DOUGLAS ALLEN GREEN
Medical Practice in San Diego, CA
License number
Pennsylvania MT186270
Category
Medicine
Type
Graduate Medical Trainee
Address
Address
2
San Diego, CA 92103
Pennsylvania
Pennsylvania
Personal information
See more information about DOUGLAS ALLEN GREEN at radaris.comName
Address
Phone
4857 Glencannon St, Santa Rosa, CA 95405
4712 Holston River Ct, San Jose, CA 95136
498 State Route 93, Sugarloaf, PA 18249
4628 Don Lorenzo Dr APT D, Los Angeles, CA 90008
44119 Greentree Ct, Lancaster, CA 93535
Professional information
See more information about DOUGLAS ALLEN GREEN at trustoria.com
Dr. Douglas A Green, Sayre PA - MD (Doctor of Medicine)
Dr. Douglas A Green, Sayre PA - MD (Doctor of Medicine)
Specialties:
Diagnostic Radiology
Address:
1 Guthrie Sq, Sayre 18840
31700 Temecula Pkwy, Temecula 92592
(951) 600-3811 (Phone)
36320 Inland Valley Dr SUITE 101, Wildomar 92595
San Diego Office
200 W Arbor Dr, San Diego 92103
(619) 543-6222 (Phone), (619) 543-2152 (Fax)
31700 Temecula Pkwy, Temecula 92592
(951) 600-3811 (Phone)
36320 Inland Valley Dr SUITE 101, Wildomar 92595
San Diego Office
200 W Arbor Dr, San Diego 92103
(619) 543-6222 (Phone), (619) 543-2152 (Fax)
Certifications:
Diagnostic Radiology, 2010
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Pittsburgh / Main Campus
Graduated: 2002
University of Pittsburgh / Main Campus
Graduated: 2002
Method Of Identifying Immunosuppressive Agents
Method Of Identifying Immunosuppressive Agents
US Patent:
6828091, Dec 7, 2004
Filed:
Aug 2, 2001
Appl. No.:
09/920332
Inventors:
Shailaja Kasibhatla - San Diego CA
Douglas R. Green - San Diego CA
Ben Tseng - San Diego CA
Douglas R. Green - San Diego CA
Ben Tseng - San Diego CA
Assignee:
Cytovia, Inc. - San Diego CA
International Classification:
C12Q 125
US Classification:
435 4, 435 724, 435 772, 435 792
Abstract:
A method for identifying therapeutically effective immunosuppressive agents by screening such agents for those which induce apoptosis in activated T cells is disclosed. T cells were isolated then activated and treating with various test compounds. A caspase substrate is added to detect caspase activation and apoptosis in the cells. Compounds which stimulate caspase activation and apoptosis are also tested against resting T cells to determine those agents which are more effective in activated T cells compared to resting T cells. Compounds with this selectivity are effective in treating immunopathological disorders such as arthritis, graft rejection, graft versus host disease, inflammatory bowel syndrome and the like.
Therapy For Cellular Accumulation In Chronic Inflammatory Diseases
Therapy For Cellular Accumulation In Chronic Inflammatory Diseases
US Patent:
6747013, Jun 8, 2004
Filed:
Jul 29, 1999
Appl. No.:
09/363997
Inventors:
Gary S. Firestein - Del Mar CA
Nathan J. Zvaifler - La Jolla CA
Douglas R. Green - San Diego CA
Nathan J. Zvaifler - La Jolla CA
Douglas R. Green - San Diego CA
Assignee:
The Regents of the University of California - Oakland CA
La Jolla Institute for Allergy and Immunology - San Diego CA
La Jolla Institute for Allergy and Immunology - San Diego CA
International Classification:
A61K 4800
US Classification:
514 44, 4353201, 435325, 435455, 536 235, 424 936
Abstract:
The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes gene delivery and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods for detecting cellular accumulation diseases.
Caspase Inhibitors And The Use Thereof
Caspase Inhibitors And The Use Thereof
US Patent:
6355618, Mar 12, 2002
Filed:
Apr 7, 2000
Appl. No.:
09/545565
Inventors:
Sui Xiong Cai - San Diego CA
Eckard Weber - San Diego CA
Yan Wang - San Diego CA
Gordon B. Mills - Houston TX
Douglas R. Green - San Diego CA
Eckard Weber - San Diego CA
Yan Wang - San Diego CA
Gordon B. Mills - Houston TX
Douglas R. Green - San Diego CA
Assignee:
Cytovia, Inc. - Irvine CA
International Classification:
A61K 3805
US Classification:
514 19, 546335, 549287, 549405, 560 38, 560 39, 560125, 560169, 560170, 562450, 562507, 562561, 562564, 5142375, 514357, 514456, 514478, 514557, 514563
Abstract:
The present invention is directed to novel dipeptide thereof, represented by the general Formula I: where R -R , X and Y are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
Douglas Allen Green, San Diego CA
Douglas Allen Green, San Diego CA
Specialties:
Radiologist
Address:
200 W Arbor Dr, San Diego, CA 92103
1 Guthrie Sq, Sayre, PA 18840
31700 Temecula Pkwy, Temecula, CA 92592
1 Guthrie Sq, Sayre, PA 18840
31700 Temecula Pkwy, Temecula, CA 92592
Caspase Inhibitors And The Use Thereof
Caspase Inhibitors And The Use Thereof
US Patent:
2004011, Jun 17, 2004
Filed:
Nov 26, 2003
Appl. No.:
10/721338
Inventors:
Sui Cai - San Diego CA, US
Eckard Weber - San Diego CA, US
Yan Wang - San Diego CA, US
Gordon Mills - Houston TX, US
Douglas Green - San Diego CA, US
Eckard Weber - San Diego CA, US
Yan Wang - San Diego CA, US
Gordon Mills - Houston TX, US
Douglas Green - San Diego CA, US
Assignee:
Cytovia, Inc.
International Classification:
A61K038/04, C07K005/04
US Classification:
514/019000, 546/201000, 546/210000, 546/229000, 546/272700, 546/277400, 546/336000, 548/338100, 548/495000
Abstract:
The present invention is directed to novel dipeptide thereof, represented by the general Formula I:
where R-R, X and Y are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
Substituted 2-Aminobenzamide Caspase Inhibitors And The Use Thereof
Substituted 2-Aminobenzamide Caspase Inhibitors And The Use Thereof
US Patent:
2003018, Sep 25, 2003
Filed:
May 9, 2003
Appl. No.:
10/434335
Inventors:
Sui Cai - San Diego CA, US
Yan Wang - Austin TX, US
Eckard Weber - San Diego CA, US
Gordon Mills - Houston TX, US
Douglas Green - San Diego CA, US
Yan Wang - Austin TX, US
Eckard Weber - San Diego CA, US
Gordon Mills - Houston TX, US
Douglas Green - San Diego CA, US
Assignee:
Cytovia, Inc.
International Classification:
A61K038/08, A61K038/06, A61K038/05, C07K007/06, C07K005/06, C07K005/04
US Classification:
514/017000, 514/019000, 514/018000, 530/330000, 530/331000
Abstract:
The present invention is directed to novel 2-aminobenzamide thereof, represented by the general Formula I:
where R-R, X, and A-D are defined herein. The present invention also relates to the discovery that compounds having Formula I are potent inhibitors of caspases and apoptotic cell death. Therefore, the inhibitors of this invention can retard or block cell death in a variety of clinical conditions in which the loss of cells, tissues or entire organs occurs.
Methods For Treating Arthritis By Administering An Apoptosis Regulator
Methods For Treating Arthritis By Administering An Apoptosis Regulator
US Patent:
6004942, Dec 21, 1999
Filed:
Aug 30, 1996
Appl. No.:
8/705243
Inventors:
Gary S. Firestein - Del Mar CA
Nathan J. Zvaifler - La Jolla CA
Douglas R. Green - San Diego CA
Nathan J. Zvaifler - La Jolla CA
Douglas R. Green - San Diego CA
Assignee:
The Regents of the University of California - Oakland CA
International Classification:
A61K 4800, C12N 500, C12N 1500
US Classification:
514 44
Abstract:
The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes gene delivery and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods for detecting cellular accumulation diseases.
Therapy For Cellular Accumulation In Chronic Inflammatory Diseases
Therapy For Cellular Accumulation In Chronic Inflammatory Diseases
US Patent:
2008004, Feb 21, 2008
Filed:
Aug 28, 2007
Appl. No.:
11/846351
Inventors:
Gary Firestein - Del Mar CA, US
Nathan Zvaifler - La Jolla CA, US
Douglas Green - San Diego CA, US
Nathan Zvaifler - La Jolla CA, US
Douglas Green - San Diego CA, US
Assignee:
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA
International Classification:
A61K 31/711, A61K 9/00, A61K 9/127, A61P 1/00, A61P 19/02
US Classification:
424450000, 424400000, 514044000
Abstract:
The present invention provides a novel method for the treatment of cellular accumulation in chronic inflammatory diseases such as rheumatoid arthritis. The method includes gene delivery and gene expression that is capable of enhancing apoptosis of accumulating cells and those cells which recruit accumulating cells. Also provided are diagnostic methods for detecting cellular accumulation diseases.
Enhancement Of Adoptosis Using Antisense Oligonucleotides
Enhancement Of Adoptosis Using Antisense Oligonucleotides
US Patent:
5583034, Dec 10, 1996
Filed:
Feb 22, 1994
Appl. No.:
8/200723
Inventors:
Douglas R. Green - San Diego CA
Thomas G. Cotter - Co. Kildare, IE
Thomas G. Cotter - Co. Kildare, IE
Assignee:
La Jolla Institute for Allergy and Immunology - La Jolla CA
International Classification:
C12N 510, C12N 508, C07H 2104, C12Q 168
US Classification:
4352402
Abstract:
A method is disclosed for enhancement of the efficacy of therapeutic treatment for inducing cell death in a cell having an anti-apoptotic gene by the enhancement of apoptosis. An antisense oligonucleotide is disclosed which hybridizes with the nucleic acid sequence of the anti-apoptotic gene. The oligonucleotide is administered to the cell in an amount sufficient to inhibit expression of the gene, thus rendering the cell susceptible to induction of apoptosis, and consequently achieving higher efficacy of therapeutic treatment.